Antipsychotic-Induced Tardive Dyskinesia: From biological basis to clinical management.

Antipsychotic-Induced Tardive Dyskinesia: From biological basis to clinical management. Expert Rev Neurother. 2017 Jul 28;: Authors: Salem H, Pigott T, Zhang XY, Zeni C, Teixeira AL Abstract INTRODUCTION: Tardive dyskinesia (TD) is a chronic and disabling movement disorder with a complex pathophysiological basis. A significant percentage of patients does not receive correct diagnosis, resulting in delayed or inaccurate treatment and poor outcome. Therefore, there is a critical need for prompt recognition, implementation of efficacious treatment regimens and long-term follow up of patients with TD. Areas covered: The current paper provides an overview of emerging data concerning proposed pathophysiology theories, epidemiology, risk factors, and therapeutic strategies for TD. Expert Commentary: Despite considerable research efforts, TD remains a challenge in the treatment of psychosis as the available strategies remain sub-optimal. The best scenario will always be the prophylaxis or prevention of TD, which entails limiting the use of antipsychotics. PMID: 28750568 [PubMed - as supplied by publisher]
Source: Expert Review of Neurotherapeutics - Category: Neurology Tags: Expert Rev Neurother Source Type: research